Is Novavax Stock a Buy Now?
Biotech company (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and tribulations in this period, however. And in the past three years, the stock is down by a whopping 94%.
If Novavax can mount a comeback, now may be as good a time as any to press the buy button while its shares are changing hands for just about $5.46 apiece.
Or perhaps Novavax hasn't hit rock bottom yet and will continue to see its share price plunge. Which scenario is more likely? Let's dig in and find out.
Source Fool.com
Novavax Inc. Aktie
6,87 €
1,93 %
Novavax Inc. ist ein kleiner Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 11 € für Novavax Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 6.87 €.
